Usage of Electronic Signatures-Notification to Regulatory [Software]

posted by Debbie – India, 2010-09-29 11:49 (5320 d 05:53 ago) – Posting: # 5954
Views: 4,059

Hi,

Is the usage of electronic signatures in Nugenesis SDMS (for bioanalytical data of Bioequivalence study) needs to be notified to FDA and other regulatory authorities before/after start of usage.

As per 21 CFR Part 11 section 11.100 (c), the usage of electronic signatures to be notified to FDA.

Is the requirement applies to electronic signatures of Nugenesis SDMS for the handling of bioanalytical chromatographic data?

Is there any similar requirement from other regulatory regions like EMA, TGA Canada etc.

please provide your valuable inputs.

Regards,

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,670 registered users;
20 visitors (0 registered, 20 guests [including 0 identified bots]).
Forum time: 17:42 CEST (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5